Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BYOncoimmunology

Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes.

  • Anne-Laure Mallard de La Varende1
  • Marine Fidelle1
  • Guido Kroemer2,3,4
  • Laurence Zitvogel1
4 affiliations
  1. 1Gustave Roussy (GRCC), ClinicObiome, Inserm UMR1367, Microbiota and Mucosal Immunity for Cancer Immunotherapy, Université Paris-Saclay, Villejuif, France.
  2. 2Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale Contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.
  3. 3INSERM US23, Analyse moléculaire, modélisation et imagerie de la maladie Cancéreuse, Plateformes de Métabolomique et de Criblage Cellulaire Haut Débit, Université Paris-Saclay, Villejuif, France.
  4. 4Institut Du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Read full textPDFDOICite

Abstract

In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.

Related

  1. Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study
    Sara Elena Rebuzzi, Vanja Miskovic, Giuseppe Fornarini +19
    npj Precision OncologyPeer-reviewedCC BYFull textOncologyDOAJ
  2. Artificial intelligence–enabled nursing surveillance for pediatric cancer immunotherapy: integrating biomarkers, patient-reported outcomes, and long-term toxicity management
    Yi Peng, Qiong Kou, Sihong Guo +3
    Frontiers in medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  3. 1144 Spatially organized cytokine responses in malignant cells predict immunotherapy response
    Keene Lee, Mehri Monavarian, Andrey Finegersh +4
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. 424 Tumour-homing T cells in the blood predict the efficacy of anti-PD-1 immunotherapy in melanoma patients
    Shahneen Sandhu, Anupama Pasam, Andreas Behren +13
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Peak Total Bile Acids and Adverse Perinatal Outcomes in Intrahepatic Cholestasis of Pregnancy: A Retrospective Cohort Study with Threshold Analysis
    Türkan Dikici Aktaş, Özgür Volkan Akbulut, Bengisu Elüstü Çakır +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{varende2026biomarkers,
  title = {{Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes.}},
  author = {Anne-Laure Mallard de La Varende and Marine Fidelle and Guido Kroemer and Laurence Zitvogel},
  journal = {Oncoimmunology},
  year = {2026},
  month = oct,
  doi = {10.1080/2162402x.2026.2748140},
  url = {https://europepmc.org/article/MED/42878219},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes.
AU  - Anne-Laure Mallard de La Varende
AU  - Marine Fidelle
AU  - Guido Kroemer
AU  - Laurence Zitvogel
PY  - 2026
DA  - 2026/10/15
JO  - Oncoimmunology
DO  - 10.1080/2162402x.2026.2748140
UR  - https://europepmc.org/article/MED/42878219
AB  - In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.
SN  - 2162-4011
SN  - 2162-402X
ER  -